Search the Newsreel

Halozyme Therapeutics HALO Surges After Big Earnings Beat And Guidance Hike

Halozyme Therapeutics (HALO) surged by 19.44% after reporting Q2 earnings that significantly beat expectations, with non-GAAP EPS at $2.28 and revenue at $481M. The company also raised its 2026 non-GAAP EPS and revenue guidance above Street estimates, driven by strong royalty growth and new …

Solid Rent Growth and Higher Asset Quality Make Charter Hall Retail REIT Attractive

Charter Hall Retail REIT (ASX:CQR) Shares Trade Below Asset Backing As Debt Risks Linger

Halozyme Therapeutics (NASDAQ:HALO) Upgraded to "Outperform" at Leerink Partners

Leerink Partners has upgraded Halozyme Therapeutics (NASDAQ:HALO) from "market perform" to "outperform," setting a $110 price target. This upgrade follows Halozyme's strong quarterly results, with revenue up 47.7% year-over-year and EPS significantly beating estimates, leading management to raise its fiscal 2026 outlook. The company …

John Marshall Bancorp FY26 Q2 net income rises 37.5% to $7.02 million

John Marshall Bancorp reported a significant increase in Q2 FY26 net income, rising 37.5% year over year to $7.02 million, with diluted EPS up 38.9% to $0.5. The company's net interest income grew by 16.1% and net interest margin widened, while non-interest income more …

HALOZYME THERAPEUTICS, INC. : LEERINK PARTNERS RAISES TO OUTPERFORM FROM MARKET PERFORM; RAISES TARGET PRICE TO $110 FROM $83

Leerink Partners has upgraded Halozyme Therapeutics, Inc. (HALO.O) from Market Perform to Outperform. The firm also increased its target price for Halozyme Therapeutics to $110, up from the previous $83. This suggests a more positive outlook on the company's stock performance.

John Marshall Bancorp Announces Strong Q2 2026 Financial Performance

John Marshall Bancorp, Inc. has reported its second-quarter and year-to-date financial results for 2026 by filing its Form 10-Q with the U.S. Securities and Exchange Commission. The Virginia-based bank holding company announced strong financial performance for the period ending June 30, 2026. To access …

Halozyme Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:HALO) 2026-08-07

Halozyme Therapeutics, Inc. (HALO) has published its Q2 2026 earnings call presentation, reporting significant financial beats. The company's EPS of $2.28 surpassed estimates by $0.46, and revenue reached $481.00M, exceeding expectations by $78.72M and showing a 47.67% year-over-year increase. This presentation was released in …

Hindustan Aeronautics shares gain 11% in a month; all eyes on Q1 result amid easing engine supply issues

Challenger Gold (ASX:CEL) Shares Rise as Hualilan Moves From Development Into Gold Production

Charter Hall Retail REIT (ASX:CQR) FY26 Profit Rises as Refinancing Resets Debt Position

Hindustan Aeronautics Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

HALOZYME THERAPEUTICS, INC. 2026: Revenue $481M, EPS $1.9— 10-Q Summary

HALOZYME THERAPEUTICS, INC. reported strong financial results for the 2026 quarter, with revenue reaching $481 million and diluted EPS of $1.9. This growth was primarily driven by increased royalties, particularly from products like DARZALEX SC and VYVGART Hytrulo, and significant growth in bulk rHuPH20 …

Charter Hall Retail REIT (ASX:CQR) Reports FY26 Growth as Convenience Retail Strategy Delivers Portfolio Expansion

Earnings call transcript: Charter Hall Retail REIT posts steady FY 2026 growth, shares rise

Enterprise value to EBITDA forward of Robert Half Inc. – SWB:RHJ

This article provides financial data for Robert Half Inc. (RHJ) traded on the Stuttgart Stock Exchange, specifically focusing on its enterprise value to EBITDA forward. It indicates that the market was closed with no trades recorded for the period. The data presented is sourced …

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Halozyme Therapeutics (HALO) reported revenue of $481 million, up 47.7% over the same period last year. EPS came in at $2.28, compared to $1.54 in the year-ago quarter. The reported revenue represents a surprise of +17.44% over the …

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

Halozyme Therapeutics (HALO) reported Q2 earnings of $2.28 per share and revenues of $481 million, both exceeding Zacks Consensus Estimates. The company has consistently surpassed revenue estimates and its shares have outperformed the S&P 500 this year, though its Zacks Rank is currently "Hold" …

Halozyme Therapeutics (NASDAQ:HALO) Beats Expectations in Strong Q2 CY2026, Guides for Strong Full-Year Sales

Halozyme Therapeutics (NASDAQ:HALO) Beats Expectations in Strong Q2 CY2026, Guides for Strong Full-Year Sales Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 47.7% year on year to $481 million. The company's full-year …

Halliburton Co. (HAL) News, Articles, Events & Latest Updates

This page provides a collection of recent news articles and updates related to Halliburton Co. (HAL). The articles primarily cover Q2 earnings reports and financial performance for various companies in the energy sector, including some of Halliburton's peers and partners, discussing revenue, earnings, and …

HALOZYME THERAPEUTICS ($HALO) Releases Q2 2026 Earnings, Stock Rises

Halozyme Therapeutics (NASDAQ: HALO) posts $481M Q2 2026 revenue

Halozyme Therapeutics (NASDAQ: HALO) reported total revenues of $481 million for Q2 2026 and $857.7 million for the first half of 2026, alongside a quarterly net income of $230 million. The biopharmaceutical company, which specializes in drug-delivery technologies like ENHANZE and Hypercon, saw significant …

Earnings Flash (HALO) Halozyme Therapeutics, Inc. Reports Q2 Revenue $481.0M, vs. FactSet Est of $402.3M

Halozyme Therapeutics, Inc. (HALO) reported robust Q2 revenue of $481.0 million, significantly exceeding FactSet's estimate of $402.3 million. The biopharmaceutical company also updated its 2026 adjusted EPS guidance to a range of $8.65-$9.00, surpassing the FactSet estimate of $7.94, and raised its 2026 revenue …

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Halozyme Therapeutics, Inc. reported record second-quarter 2026 financial results, exceeding estimates and subsequently raising its full-year 2026 financial guidance. The company saw a 48% year-over-year increase in total revenue to $481 million, with royalty revenue growing 50% to $308 million, driven by the strong …

Robert Half Inc. (NYSE:RHI) Receives Consensus Rating of "Reduce" from Brokerages

Robert Half Inc. (NYSE:RHI) has received a consensus "Reduce" rating from brokerages, based on ten analysts' reports, with an average 12-month price target of $34.75, which is below its current trading price of $40.51. The company recently met quarterly EPS and revenue expectations, reporting …

Halozyme earnings up next: Can royalty growth hit $1B target?

Halozyme Therapeutics Inc. is reporting second-quarter earnings, with investors keenly watching its partnership momentum and progress toward a $1 billion ENHANZE royalty revenue target. The company has shown strong growth and secured multiple licensing deals, contributing to its stock trading near 52-week highs. Investors …

Robert Half on AI-Proofing Your Hiring: Finding and Retaining Genuine Technology Talent, Podcast

Paul Flaharty of Robert Half discusses how AI is changing hiring practices for MSPs and technology providers, making comprehensive screening and experienced recruiters more vital than ever. The podcast also explores how organizations can retain strong technical employees through competitive compensation, flexibility, development opportunities, …

Halozyme Therapeutics, Inc. Revenue Breakdown – LSX:A0DLHS

Halozyme Therapeutics, Inc. generated 1.19 billion EUR in revenue last year, primarily from its Proprietary Enzymes, Devices, Hypercon Technology, and Surf Bio Technology segment. This revenue marks an increase from 980.78 million EUR in the previous year. The United States was the largest contributor, …

Haleon rises Thursday, outperforms market

Haleon PLC (HLN) shares rose by 1.34% to £3.71 on Thursday, outperforming the broader market as the FTSE 100 Index (UKX) fell by 0.19%. The company's stock closed 10.93% below its 52-week high of £4.16, which was reached on February 18th. This increase occurred …

What Are Wall Street Analysts' Target Price for Halliburton Stock?

Halliburton ground sign at the entrance to their headquarters in Houston By JHVEPhoto Valued at a market cap of $27 billion, Halliburton Company (HAL) is one of the world's largest providers of oilfield services and energy technology, serving exploration and production (E&P) companies across …

Can Charter Hall Group (ASX:CHC) Justify Its Valuation On Sean McMahon’s Departure?

Halozyme Therapeutics (NASDAQ:HALO) Issues Quarterly Earnings Results, Beats Expectations By $0.49 EPS

Challenger Gold Limited Applies to Quote 98,995 Ordinary Shares Issued to Directors Under Salary Sacrifice Plan

Hindustan Aeronautics shares jump over 5% on Goldman Sachs upgrade; Check key factors behind it

Projeções de Resultados: Robert Half Inc (RHI) — LPA e Crescimento de Receita

Robert Half (RHI): Buy, Sell, or Hold Post Q2 Earnings?